中国临床药学杂志2025，Vol.34Issue(6)：447-453,7.DOI:10.19577/j.1007-4406.2025.06.008
非奈利酮治疗糖尿病肾病的成本-效用分析
Cost-utility of finerenone in the treatment of diabetic kidney disease
周宇 1张铭 2李辉 2陈文文3
作者信息
- 1. 湖州学院附属南太湖医院泌尿外科,湖州 313098||苏州大学附属第二医院泌尿外科,苏州 215004
- 2. 湖州学院附属南太湖医院泌尿外科,湖州 313098
- 3. 山东第一医科大学第二附属医院药学部,泰安 271000
- 折叠
摘要
Abstract
AIM To evaluate the cost-utility of finerenone plus standard therapy in the treatment of diabetic kidney disease(DKD).METHODS Markov model was constructed based on the clinical trial and related literature.The cycle length was set at 4 months with a time horizon of 20 years,applying an annual discount rate of 5％.The willingness-to-pay(WTP)threshold was established as one time China's 2023 per capita gross domestic product(GDP).Quality adjusted life year(QALY)was the utility index,and the incremental cost-utility ratio(ICUR)was calculated accordingly.The robustness of the results was verified by one-way sensitivity analysis and probabilistic sensitivity analysis.RESULTS The ICUR of finerenone combined with standard treatment was 43 035.372 8 yuan/QALY,which was lower than the WTP threshold of 89358 yuan/QALY in the study.The results of one-way sensitivity analysis showed that the finerenone price greatly influenced ICUR,but did not affect the robustness of the model.The results of probabilistic sensitivity analysis showed that finerenone plus the standard treatment regimen was more economical under the WTP threshold of the study.CONCLUSION Finerenone combined with standard therapy is economical in DKD patients compared with standard therapy.关键词
非奈利酮/糖尿病肾病/药物经济学/马尔可夫模型/成本-效用分析Key words
finerenone/diabetic kidney disease/pharmacoeconomics/Markov model/cost-utility analysis分类
医药卫生引用本文复制引用
周宇,张铭,李辉,陈文文..非奈利酮治疗糖尿病肾病的成本-效用分析[J].中国临床药学杂志,2025,34(6):447-453,7.
